GeneDx Holdings Corp vs Materials Select Sector SPDR Fund — how do they compare? GeneDx Holdings Corp trades at $82.37 (market cap $2.44B), while Materials Select Sector SPDR Fund trades at $52.68. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| WGS | XLB | |
|---|---|---|
Market Cap | $2.44B | — |
Sector | Technology | — |
52-Week High | $167.51 | $53.62 |
52-Week Low | $34.51 | $42.23 |
Enterprise Value | $2.48B | — |
Signals from Pluang's Aura AI — not financial advice
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
XLB (Materials Select Sector SPDR ETF) trades at $52.68, down 0.94% on the day, while maintaining a bullish technical outlook with strong moving average support. The materials sector benefits from infrastructure spending and AI-related demand, though recent price action suggests some consolidation after the sector rebound. Technical indicators show mixed signals with overbought short-term RSI but strong trend momentum.
The ETF offers diversified exposure to materials companies with cyclical recovery potential, though valuation metrics appear limited after recent gains. Key risks include economic sensitivity and commodity price volatility, while positive earnings momentum and institutional interest provide support for long-term investors.
Trailing returns across standard periods
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →